Analyst Ratings for NewAmsterdam Pharma Co NV (NAMS)
NAMS Rating Summary
NAMS Price Target Summary
- Highest: $52.00 (Scotiabank)
- Lowest: $36.00 (Needham)
- Average: $43.60
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$43.60 (+86.6%)
* Over Last 12-Mos
Rating Score: 10 / 10
Percentile Rank: 95%
Avg. $ Target:
$43.60 (+86.6%)
* Over Last 12-Mos
Rating Score: 10 / 10
Percentile Rank: 95%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/30/2024 | H.C. Wainwright | Ed Arce | New Coverage | Buy (N/A) |
48.00 (N/A) |
25.86 (23.37) |
-9.63% | Details |
| 8/28/2024 | Needham | Serge Belanger | New Coverage | Buy (N/A) |
36.00 (N/A) |
16.77 (23.37) |
39.36% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
